SWOG 0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw in Cancer Patients with Bone Metastasis Starting Zoledronic Acid Treatment
June 10, 2009
Cancer - Side Effect Management
Participant must have bone metastasis from multiple myeloma, solid tumors, or other malignancy for which intravenous bisphosphonate has clinical indications in the treatment of metastatic bone disease; All participants must be planning to receive zoledronic acid (as their sole bisphosphonate therapy) within 30 days after registration. (NOTE: Bisphosphonate therapy will continue thereafter as clinically indicated.); Participants must not have a pre-existing diagnosis of ONJ; Participants must not have a history of radiation to the maxillofacial area administered for therapeutic intent in the treatment of cancer.